Kinsale Capital Group Insider Sold Shares Worth $817,249, According to a Recent SEC Filing-March 2024-www.financetom.com

Kinsale Capital Group Insider Sold Shares Worth $817,249, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Kinsale Capital Group Insider Sold Shares Worth $817,249, According to a Recent SEC Filing

Mar 11, 2024 1:31 PM

04:11 PM EDT, 03/11/2024 (MT Newswires) -- Brian D. Haney, President and COO, on March 07, 2024, sold 1,500 shares in Kinsale Capital Group ( KNSL ) for $817,249. Following the Form 4 filing with the SEC, Haney has control over a total of 154,459 shares of the company, with 90,628 shares held directly and 63,831 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1669162/000109690624000379/xslF345X03/form4.xml

Price: 508.67, Change: +2.65, Percent Change: +0.52

Previous page： Progressive Insider Sold Shares Worth $402,612, According to a Recent SEC Filing Next page： I-Mab to Prioritize Givastomig as Lead Program; Shares Rise

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Progressive Insider Sold Shares Worth $402,612, According to a Recent SEC Filing

Jan 6, 2025

02:13 PM EST, 01/06/2025 (MT Newswires) -- John Jo Murphy, Claims President, on January 03, 2025, sold 1,663 shares in Progressive (PGR) for $402,612. Following the Form 4 filing with the SEC, Murphy has control over a total of 60,166 shares of the company, with 45,289 shares held directly and 14,878 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/80661/000112760225000665/xslF345X05/form4.xml Price: 241.09, Change: -1.13,...

I-Mab to Prioritize Givastomig as Lead Program; Shares Rise

Jan 6, 2025

02:19 PM EST, 01/06/2025 (MT Newswires) -- I-Mab ( IMAB ) shares were up more than 16% in recent Monday trading after the company said it will focus on advancing givastomig as its lead program targeting first-line metastatic gastric cancers, with further potential in other solid tumors. A dose escalation study of givastomig with nivolumab plus chemotherapy has been completed,...

Rollins Expected to Deliver Continued Revenue Gains in 2025, RBC Says

Jan 6, 2025

02:09 PM EST, 01/06/2025 (MT Newswires) -- Rollins (ROL) is poised to grow revenue this year in the high single-percentage digits or low double-percentage digits over 2024 levels, supported both by organic growth and likely merger-and-acquisition activity for the pest-control company, analysts at RBC Capital Markets said Monday in a note. The analysts continue to project around $3.67 billion in...

Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing

Jan 6, 2025

02:13 PM EST, 01/06/2025 (MT Newswires) -- Jonathan Young, Chief Operating Officer, on January 02, 2025, sold 10,000 shares in Akero Therapeutics ( AKRO ) for $280,330. Following the Form 4 filing with the SEC, Young has control over a total of 278,083 shares of the company, with 218,083 shares held directly and 60,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1744659/000095017025001850/xslF345X05/ownership.xml Price:...